Key takeaways from ‘The Operational Realities of Protocol Amendments’ panel discussion at the Advarra Innovation Summit in Research Triangle Park
Estimated reading time: 8 minutes
Protocol amendments have long been treated as an inevitable byproduct of complex study design. But a recent panel discussion at the Advarra Innovation Summit in Research Triangle Park reframed that assumption more critically: What if amendments aren’t just disruptions, but signals—predictable indicators of where protocols fall short in the real world?
That question anchored a wide-ranging conversation moderated by Ashley Davidson, SVP, head of product at Advarra, and featuring Earl Seltzer, executive director of strategy and innovation at CTI; Ashlee Lang, director of the Office of Clinical Research at University of Rochester CTSI; and Lindsey Kells, associate director of site activation at Vertex Pharmaceuticals.
Drawing from their sponsor, contract research organization (CRO), and site perspectives, the group explored how amendments unfold operationally and where the industry still has an opportunity to reduce avoidable amendments earlier.
Amendments as signals, not surprises
The discussion opened with a data-driven perspective from Ashley, who shared early insights from Advarra’s newly released trend report: Across tens of thousands of protocols and amendments, patterns are emerging, suggesting that while amendment frequency may not vary dramatically across therapeutic areas, the type and impact of those amendments do.
In Rare Disease studies, for example, eligibility criteria often drive changes. In Cardiovascular trials, endpoint-related amendments can have an outsized operational impact, even in studies that appear more operationally efficient at baseline.
The implication, the panel agreed, is clear: Amendments are not random. They follow patterns that, if identified early enough, can inform better protocol design.
Ashley framed the central tension succinctly: Amendments are often the first real signal that a study is encountering operational friction, and by the time that signal appears, the cost—across timelines, budgets, and patient burden—is already significant.
Where amendments disrupt operations sooner than you think
When amendments are introduced mid-study, the breakdown rarely starts where sponsors expect.
Ashlee, representing the site perspective, pointed to a surprisingly basic failure point: awareness that the protocol was amended, and how.
“We get a notification from the central IRB [institutional review board] that version two of the protocol has been approved, and our immediate question is, ‘What is version two?’” she said. “We’re scrambling to obtain the redlined protocol and the updated consent form so we can evaluate possible contract and budget impacts.”
That lack of synchronized communication creates immediate friction. Sites are forced into reactive mode before they even understand what’s changed.
Earl expanded on the downstream effects.
“When you ask operational teams what breaks first, they’ll likely point to impacts on patients and sites,” he said. “Amendments can disrupt patient visits, consent status, and continuity of care almost immediately. There’s a cascade effect that slows implementation, and sites become understandably hesitant to move forward without full approval because even minor changes can create significant additional work.”
Lindsey added that sponsors often underestimate the complexity of implementation.
“Study teams can often focus on IRB approval as the milestone to target,” she said, “but you can’t implement without contracts, training, and supplies, as applicable. All the pieces have to come together.”
The result is a fragmented activation process where parallel workflows—including regulatory, financial, and operational—move at different speeds, creating delays that compound quickly.
The hidden cost of ‘small’ changes
One of the most consistent themes across the panel was the disproportionate impact of seemingly minor protocol adjustments.
On paper, a change might look trivial—a wording update, a modified assessment, an added endpoint. But in practice, it sets off a chain reaction.
“There’s often too little appreciation for the amount of rework that even minor amendments can trigger,” Earl said. “You start something, then you amend, and suddenly you’re doing work all over again. It’s time-consuming and frustrating.”
That rework could include:
- Budget and contract renegotiation.
- Clinical trial management system (CTMS) updates and schedule-of-events revisions.
- Data management and interactive response technology (IRT) adjustments.
- Technology updates, including translations and licensing.
- Retraining across site and sponsor teams.
For sites, the complexity intensifies when patients are already enrolled.
“You get stuck in this strange limbo,” Ashlee said, “where maybe they’re consented on version one, and now version two has just been approved, and they have a visit coming up. What do you do?”
These scenarios introduce not only operational risk, but also compliance ambiguity, requiring ongoing documentation—such as notes to file, visit-level explanations, and monitoring follow-up—to justify and memorialize both clinical and operational decisions that were made long after the amendment itself.
The design gap between science and reality
While some amendments are necessary to address scientific or safety considerations, why do so many avoidable ones still happen so frequently?
The panel pointed to a persistent disconnect: Protocols are often scientifically rigorous but operationally fragile.
“A lot of protocols are designed that way,” Earl said. “There isn’t enough deep operational feasibility built into the design phase.”
And this gap shows up in multiple ways. Eligibility criteria may reflect outdated clinical practice. Visit schedules may impose unrealistic burdens. Procedures that are scientifically justified may be unacceptable to patients.
Ashlee shared a stark example.
“We had a study requiring an additional bone marrow biopsy within two weeks of screening,” she said. “Trying to explain that requirement to patients who have already had multiple biopsies—it was very difficult. Enrollment suffered.”
The issue is that scientific intent can sometimes collide with operational constraints in the absence of an integrated perspective—a lack of operational context, site input, and patient insight. Protocols are often developed without sufficient input from the people responsible for executing them and those participating in them.
Bringing the right voices upstream
Across all three perspectives, the solution converged on one principle: earlier, deeper collaboration.
That includes:
- Engaging practicing physicians to validate eligibility criteria against current standards.
- Incorporating patient feedback to assess burden and feasibility.
- Involving sites and CROs in operational feasibility assessments.
- Stress-testing protocols against real-world execution scenarios.
Lindsey described how Vertex approaches this proactively.
“We oftentimes send protocol concepts to lead investigators to get feedback on whether the design is executable,” she said. “We also run patient insight studies when exploring a new patient population to understand what’s too burdensome and what’s acceptable.”
That feedback can shape everything from visit schedules to endpoint selection.
At the same time, flexibility within protocols—such as investigator discretion—can help reduce the need for amendments, though it introduces its own challenges.
“Leaving something up to discretion can also lead to back-and-forth conversations if discretion differs between investigators and medical monitors, which can slow the enrollment process,” said Lindsey.
The balance between standardization and flexibility remains delicate, but intentional design choices, inspired by site input and patient insight, can reduce the need for reactive changes later.
Designing for alignment, not revision
One of the more practical strategies the panel discussed was aligning key documents earlier in the process.
Lindsey highlighted the value of drafting the informed consent form template alongside the protocol.
“When you review them side by side, you catch inconsistencies early,” she said. “Sometimes that leads to changes in the protocol itself before it ever reaches a site.”
This approach can expose misalignments across functional teams—clinical development, medical writing, and regulatory—before they become embedded in the study.
It also reinforces a broader shift: moving from amendment-driven correction to design-stage alignment.
A shift from reaction to prediction
By the close of the discussion, a clear narrative had emerged. Amendments are not just operational hurdles, they can help us more precisely identify where design assumptions break down, where design meets reality, and where scientific intent collides with execution constraints.
The opportunity now is to treat those signals proactively.
Patterns across therapeutic areas can inform design decisions. Early stakeholder engagement can surface feasibility risks. Integrated workflows can reduce downstream fragmentation.
As Ashlee put it, the goal is simple but often overlooked: ensuring that protocols are not only scientifically sound, but operationally executable and acceptable to patients.
The industry has long accepted amendments as inevitable. The more compelling question, and one that this panel brought into sharper focus, is this: How many of those amendments were avoidable all along?